Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology.

Similar presentations


Presentation on theme: "Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology."— Presentation transcript:

1 Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology Dalian University of Technology Dalian, China 2015. 3.16.

2 Each day: 1,500 people in the U.S. will die of cancer Each year: 1,220,100 people in the U.S. will be diagnosed with cancer Ultimately: One in four people in the U.S. will die of cancer Cancer Statistics Leading Cancer Types: Breast: 16.3% of all cancer cases with a 40% increase since 1973 7.8% of all cancer deaths Lung: 13.2% of all cancer cases with a 1.6 percent per year decline from 1992 to 1998 29% of all cancer deaths Prostate: 14.8% of all cancer cases with an average 5.7 % per year decline from 1992 to 1998 5.9% of all cancer deaths Colorectal: 11.6% of all cancer cases with sharply different rates among racial and ethnic groups 10.5% of all cancer deaths www.seer.cancer.govwww.seer.cancer.gov www.cdc.gov/cancer/ www.naaccr.org/www.cdc.gov/cancer/www.naaccr.org/

3 Leading New Cancer Cases and Deaths – 2013 Estimates ?

4 Challenge for administration of Breast Cancer Challenge in the treatment of breast cancer: Recurrence and relapse, which was initiated and maintained by remaining cancer stem cells (CSCs) from either residual tumors or those with intrinsic resistance to adjuvant therapy.

5 Breast Cancer Stem Cells (BCSCs) The breast CD44 + cells are basal-like, similar to normal breast stem cells; CD24 + cells express markers of luminal differentiation. CD44 + /CD24 - breast cancer cells  preferentially survive treatment compared to the more differentiated cancer cells. Thus, being used as therapeutic target cells.

6 6 Biogenesis of microRNAs

7 BenignDCISIDC * Regulatory Role of microRNAs in Tumoregensis ? Zhao et al., 2011 Breast Cancer Res Trt

8 CSC Specific therapy Tumor regression Convensional cancer therapy Tumor relapse miR-34a: CSC specific therapy? miR-34a:  CSC self-renewal  apoptosis? X

9 Reciprocal endogenous expression of miR-34a and SIRT1 in CD44+/CD24− BCSCs

10 Down-regulation of SIRT1 and over-expression of miR- 34a inhibit cell growth and colony formation abilities

11 Endogenous expression of SIRT1 in CD44+/CD24− BCSCs

12 Inhibitory effect of miR-34a-SIRT1 axis on cell proliferative potential in MCF-7 cells

13

14 Repression of miR-34a-SIRT1 axis on the proportion of CD44+/CD24- BCSCs

15 Repression of miR-34a-SIRT1 axis mammosphere formation capacity

16 miR-34a suppressed expression of stem cell markers

17 Alteration of miR-34a-SIRT1 axis supressed Nanog

18 Modulation of miR-34a- SIRT1 axis enhanced MCF-7 cell apoptosis

19 MiR-34a over-expression or silenced SIRT1 inhibited tumor growth in vivo.

20 Subcutaneous tumor regeneration from MCF-7 cells infected with lentivirus-miR-34a(miR-34a) or shRNA- SIRT1(shRNA-SIRT1)

21

22 qRT-PCR analyses of miR-34a expression in each group of xenograft tissues

23 Protein levels of SIRT1, and ALDH1 in each group of mice tumors

24 miR-34a caused breast cancer stem cell apoptosis through its target genes

25 Acknowledgements This research is supported by Chinese NSFC (8120734) DLUT seed grant (1003852014) School of Pharmaceutical Science & Technology Dalian University of Technology Dalian, China


Download ppt "Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology."

Similar presentations


Ads by Google